VPT:CC - Ventripoint to Exhibit at the 58th Annual Meeting of the Association for European Paediatric and Congenital Cardiology
(TheNewswire)
Toronto, Ontario – TheNewswire – May 28, 2025 -Ventripoint Diagnostics Ltd. ("Ventripoint" or the"Company"), (TSXV:VPT; OTC:VPTDF) is pleased to announce itsparticipation in the 58th Annual Meeting of the Association forEuropean Paediatric and Congenital Cardiology (AEPC) being held on May28th-31st 2025 in Hamburg, Germany.
The AEPC is a network of specialists committed to thepractice and advancement of Congential Cardiology and closely relatedfields. Since its founding in 1963 AEPC has grown to become thelargest global association in congenital cardiology with over 1,000members. We are excited to be part of this international community andto work with its members to enhance cardiac care.
This year’s meeting is hosted by the local organisingcommittee from the University Heart & Vascular Center Hamburg,Children’s Heart Medicine and Adults with Congenital Heart Disease.Ventripoint is exhibiting at the meeting and we look forward to seeingour customers, connecting with clinicians within the internationalcongenital cardiology community and continuing to expand our globalnetwork.
Our focus for this year is on growing our customer baseand working with clinicians to expand the use of VMS+ in routineclinical workflow. The advancements provided in VMS+ versions 3.2 and4.0 during the past year were designed to provide improvedproduct-user fit and better integration into clinical workflow. VMS+enables a more efficient patient journey by providing informationabout the structure and function of the heart with accuracy equivalentto cardiac MRI at the time of the patient’s first echo scan. Thisdetailed information, generated early in the care journey, leads toimproved quality of diagnosis, potentially shortening time to therapy,and increased efficacy of patient management and care throughout thepatient’s life.
“We value the opportunity to support AEPC, itsmembers within 32 European countries and their peers from othercontinents” said Ventripoint President and CEO Hugh MacNaught,“VMS+ provides the ability to deliver fast, affordable andaccessible volumetric assessments of cardiac function throughout apatient’s life journey with accuracy comparable to cardiacMRI.”
In other news:
The Company also announces it has postponed its annualmeeting of shareholders as a result of the strike notice issued byCanadian postal workers union on May 19, 2025. The Company hadscheduled the annual shareholders meeting for July 2, 2025 but isconcerned that its registrar and transfer agent may be prevented frommailing the meeting materials to shareholders on a timely basis in theevent of a postal strike. The Company will re-schedule the annualmeeting of shareholders upon resolution of the possible postal strikeactions.
About Ventripoint Diagnostics Ltd.
Ventripoint has become an industry leader in theapplication of AI (Artificial Intelligence) to echocardiography.Ventripoint's VMS products are powered by its proprietary KBRtechnology, which is the result of a decade of development andprovides accurate volumetric cardiac measurements equivalent to MRI. This affordable,gold-standard alternative allows cardiologists greater confidence inthe management of their patients. Providing better care to patientsserves as a springboard and basic standard for all of Ventripoint'sproducts that guide our future developments. In addition, VMS+ isversatile and can be used with all ultrasound systems from any vendorsupported by regulatory market approvals in the U.S., Europe andCanada.
For further information, please contact:
Hugh MacNaught
(604) 671-4201
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
About Ventripoint Diagnostics Ltd.
Ventripoint has become an industry leader in the application of AI(Artificial Intelligence) to echocardiography. Ventripoint's VMSproducts are powered by its proprietary KBR technology, which is theresult of a decade of development and provides accurate volumetriccardiac measurements equivalent to MRI. This affordable, gold-standardalternative allows cardiologists greater confidence in the managementof their patients. Providing better care to patients serves as aspringboard and basic standard for all Ventripoint's products thatguide our future developments. In addition, VMS+ is versatile and canbe used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe and Canada.
Forward Looking Statements
This news release contains forward-looking statements andforward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and information address future eventsand conditions, by their very nature they involve inherent risks anduncertainties. Actual results could differ materially from thosecurrently anticipated due to several factors and risks. Factors whichcould materially affect such forward-looking information are describedin the risk factors in the Company's most recent annual management'sdiscussion and analysis that is available on the Company's profile onSEDAR at www.sedar.com. Readers are cautioned that theforegoing list of factors is not exhaustive. The forward-lookingstatements included in this news release are expressly qualified bythis cautionary statement. The forward-looking statements andinformation contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether becauseof new information, future events or otherwise, unless so required byapplicable securities laws.
Copyright (c) 2025 TheNewswire - All rights reserved.